DDInter1763 DDInter1925
Temsirolimus is a derivative of sirolimus used in the treatment of renal cell carcinoma (RCC). It was developed by Wyeth Pharmaceuticals under the trade name Torisel. Temsirolimus was approved by the FDA in late May 2007 as well as the European Medicines Agency (EMEA) on November 2007.
Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann La Roche. After approval, Roche in collaboration with Genentech launched a broad development program.
Temsirolimus {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Vemurafenib
Temsirolimus {u} (Compound) upregulates {v} (Gene) COL11A1
COL11A1 {u} (Gene) is upregulated by {v} (Compound) Vemurafenib
Temsirolimus {u} (Compound) is included by {v} (Pharmacologic Class) Protein Kinase Inhibitors
Protein Kinase Inhibitors {u} (Pharmacologic Class) includes {v} (Compound) Vemurafenib
Temsirolimus {u} (Compound) downregulates {v} (Gene) TUBA4A
TUBA4A {u} (Gene) is downregulated by {v} (Compound) Vemurafenib
Temsirolimus {u} (Compound) causes {v} (Side Effect) Eye disorder
Eye disorder {u} (Side Effect) is caused by {v} (Compound) Vemurafenib
Temsirolimus {u} (Compound) resembles {v} (Compound) Sirolimus
Sirolimus {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Vemurafenib
Temsirolimus {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Etoricoxib
Etoricoxib {u} (Compound) resembles {v} (Compound) Vemurafenib
Temsirolimus {u} (Compound) upregulates {v} (Gene) COL11A1
COL11A1 {u} (Gene) is regulated by {v} (Gene) BRAF
BRAF {u} (Gene) is bound by {v} (Compound) Vemurafenib
Temsirolimus {u} (Compound) upregulates {v} (Gene) PAN2
PAN2 {u} (Gene) regulates {v} (Gene) ABCC1
ABCC1 {u} (Gene) is bound by {v} (Compound) Vemurafenib
Temsirolimus {u} (Compound) upregulates {v} (Gene) SETDB1
SETDB1 {u} (Gene) is associated with {v} (Disease) melanoma
melanoma {u} (Disease) is treated by {v} (Compound) Vemurafenib
Temsirolimus (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Vemurafenib (Compound)
Temsirolimus (Compound) upregulates COL11A1 (Gene) and COL11A1 (Gene) is upregulated by Vemurafenib (Compound)
Temsirolimus (Compound) is included by Protein Kinase Inhibitors (Pharmacologic Class) and Protein Kinase Inhibitors (Pharmacologic Class) includes Vemurafenib (Compound)
Temsirolimus (Compound) downregulates TUBA4A (Gene) and TUBA4A (Gene) is downregulated by Vemurafenib (Compound)
Temsirolimus (Compound) causes Eye disorder (Side Effect) and Eye disorder (Side Effect) is caused by Vemurafenib (Compound)
Temsirolimus (Compound) resembles Sirolimus (Compound) and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Vemurafenib
Temsirolimus (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Etoricoxib (Compound) and Etoricoxib (Compound) resembles Vemurafenib (Compound)
Temsirolimus (Compound) upregulates COL11A1 (Gene) and COL11A1 (Gene) is regulated by BRAF (Gene) and BRAF (Gene) is bound by Vemurafenib (Compound)
Temsirolimus (Compound) upregulates PAN2 (Gene) and PAN2 (Gene) regulates ABCC1 (Gene) and ABCC1 (Gene) is bound by Vemurafenib (Compound)
Temsirolimus (Compound) upregulates SETDB1 (Gene) and SETDB1 (Gene) is associated with melanoma (Disease) and melanoma (Disease) is treated by Vemurafenib (Compound)